Action myoclonus–renal failure syndrome

Action myoclonus–renal failure (AMRF) syndrome causes episodes of involuntary muscle jerking or twitching (myoclonus) and, often, kidney (renal) disease. Although the condition name refers to kidney disease, not everyone with the condition has problems with kidney function.

The movement problems associated with AMRF syndrome typically begin with involuntary rhythmic shaking (tremor) in the fingers and hands that occurs at rest and is most noticeable when trying to make small movements, such as writing. Over time, tremors can affect other parts of the body, such as the head, torso, legs, and tongue. Eventually, the tremors worsen to become myoclonic jerks, which can be triggered by voluntary movements or the intention to move (action myoclonus). These myoclonic jerks typically occur in the torso; upper and lower limbs; and face, particularly the muscles around the mouth and the eyelids. Anxiety, excitement, stress, or extreme tiredness (fatigue) can worsen the myoclonus. Some affected individuals develop seizures, a loss of sensation and weakness in the limbs (peripheral neuropathy), or hearing loss caused by abnormalities in the inner ear (sensorineural hearing loss). Severe seizures or myoclonus can be life-threatening.

When kidney problems occur, an early sign is excess protein in the urine (proteinuria). Kidney function worsens over time, until the kidneys are no longer able to filter fluids and waste products from the body effectively (end-stage renal disease).

AMRF syndrome typically begins causing symptoms between ages 15 and 25, but it can appear at younger or older ages. The age of onset and the course of the condition vary, even among members of the same family. Either the movement problems or kidney disease can occur first, or they can begin at the same time. Most people survive 7 to 15 years after the symptoms appear.

Frequency

AMRF syndrome is a rare condition that has been found worldwide. Its exact prevalence is unknown. At least 38 individuals with the condition have been described in the medical literature.

Causes

AMRF syndrome is caused by mutations in the \textit{SCARB2} gene. This gene provides instructions for making the LIMP-2 protein, which transports an enzyme called beta-glucocerebrosidase to cellular structures called lysosomes. Lysosomes are specialized compartments that digest and recycle materials. In these compartments, beta-glucocerebrosidase breaks down a fatty substance called glucocerebroside. The
LIMP-2 protein remains in the lysosome after transporting beta-glucocerebrosidase and is important for the stability of these structures.

*SCARB2* gene mutations associated with AMRF syndrome lead to production of an altered LIMP-2 protein that cannot get to the lysosome. As a result, the movement of beta-glucocerebrosidase to lysosomes is impaired. It is thought that a shortage of beta-glucocerebrosidase function in these structures contributes to the signs and symptoms of AMRF syndrome, although the mechanism is unclear. Researchers are working to understand why some people with *SCARB2* gene mutations have kidney problems and others do not.

**Inheritance Pattern**

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

**Other Names for This Condition**

- action myoclonus-renal failure syndrome
- action myoclonus–renal failure syndrome
- AMRF
- epilepsy, progressive myoclonic 4, with or without renal failure
- EPM4
- familial myoclonus with renal failure
- myoclonus-nephropathy syndrome
- progressive myoclonus epilepsy with renal failure

**Diagnosis & Management**

**Genetic Testing Information**

- What is genetic testing? [primer/testing/genetictesting](https://www.ncbi.nlm.nih.gov/books/NBK333437)
- Genetic Testing Registry: Epilepsy, progressive myoclonic 4, with or without renal failure

**Other Diagnosis and Management Resources**

- GeneReview: Action Myoclonus - Renal Failure Syndrome
  https://www.ncbi.nlm.nih.gov/books/NBK333437
Additional Information & Resources

Health Information from MedlinePlus

• Health Topic: Kidney Diseases
  https://medlineplus.gov/kidneydiseases.html

• Health Topic: Movement Disorders
  https://medlineplus.gov/movementdisorders.html

Additional NIH Resources

• National Institute of Neurological Disorders and Stroke: Myoclonus Fact Sheet
  https://www.ninds.nih.gov/Disorders/All-Disorders/Myoclonus-Information-Page

Educational Resources

• Baylor College of Medicine: Myoclonus
  https://www.bcm.edu/healthcare/care-centers/parkinsons/conditions/myoclonus

• MalaCards: epilepsy, progressive myoclonic, 4, with or without renal failure
  https://www.malacards.org/card/epilepsy_progressive_myoclonic_4_with_or__without_renal_failure_2

• Merck Manual Consumer Version: Myoclonus

• Orphanet: Action myoclonus-renal failure syndrome
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=163696

Patient Support and Advocacy Resources

• American Epilepsy Society
  https://www.aesnet.org/

• American Kidney Fund
  http://www.kidneyfund.org/

• Citizens United for Research in Epilepsy (CURE)
  https://www.cureepilepsy.org/

• National Kidney Foundation
  https://www.kidney.org/

Clinical Information from GeneReviews

• Action Myoclonus - Renal Failure Syndrome
  https://www.ncbi.nlm.nih.gov/books/NBK333437
Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28Myoclonic+Epilepsies,+Progressive%5BMAJR%5D%29+AND+%28action+myoclonus-renal+failure+syndrome+%5BTIAB%5D%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+3600+days%22%5Bdp%5D

Catalog of Genes and Diseases from OMIM

- EPILEPSY, PROGRESSIVE MYOClonIC, 4, WITH OR WITHOUT RENAL FAILURE
  http://omim.org/entry/254900

Sources for This Summary


  
Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19847901

  
Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22032306
Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3222607/


Reviewed: June 2016
Published: February 5, 2019

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services